The AKT1/NF-kappaB/Notch1/PTEN Axis Has an Important Role in Chemoresistance of Gastric Cancer Cells

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2013 Oct 12

PMID 24113181

Citations 38

Authors

W Zhou

X-Q Fu

L-L Zhang

J Zhang

X Huang

X-H Lu

L Shen

B-N Liu

J Liu

H-S Luo

J-P Yu

H-G Yu

Affiliations

Soon will be listed here.

Abstract

The inherent resistance of tumors to DNA damage often limits the efficacy of chemotherapy. The aim of this work is to explore the potential mechanism for development of chemoresistance in gastric cancer. Our data revealed that AKT1 mRNA and protein expression were induced by doxorubicin (a chemotherapeutic agent); the doxorubicin-induced AKT1 expression and activation increased the binding of NF-kappaB on Notch1 DNA promoter and then promoted the Notch1 transcription and expression; enhanced expression of Notch1 further upregulated PTEN expression through CBF-1 binding to PTEN DNA promoter; and inhibition of AKT1 expression and activity sensitized the gastric cancer cell to doxorubicin treatment in cultured gastric cancer cell lines and xenograft nude mice gastric cancer model. Furthermore, our data demonstrated that both Notch1 and PTEN were absent or minimally expressed in gastric cancer tissue but abundant in paired normal gastric mucosa, and the expression of Notch1 correlated with that of PTEN. Together, these novel results suggested that a novel AKT1/NF-kappaB/Notch1/PTEN axis has an important role in the development of chemoresistance in gastric cancer. Notch1 has an anti-cancer role in gastric cancer.

Citing Articles

Transplantation of gastric epithelial mitochondria into human gastric cancer cells inhibits tumor growth and enhances chemosensitivity by reducing cancer stemness and modulating gastric cancer metabolism.

Tsai H, Tsai K, Wu D, Huang Y, Lin M Stem Cell Res Ther. 2025; 16(1):87.

PMID: 39988680 PMC: 11849191. DOI: 10.1186/s13287-025-04223-7.

Cytotoxic and molecular differences of anticancer agents on 2D and 3D cell culture.

Alwahsh M, Al-Doridee A, Jasim S, Awwad O, Hergenroder R, Hamadneh L Mol Biol Rep. 2024; 51(1):721.

PMID: 38829450 DOI: 10.1007/s11033-024-09669-1.

Vil-Cre specific Slfn3KO mice exhibit sex-specific differences in lung, stomach, cecum, kidney, and proximal colon differentiation markers and Slfn family members expression levels.

Vomhof-DeKrey E, Rajpathy O, Preszler E, Basson M Biochem Biophys Rep. 2023; 36:101552.

PMID: 38076659 PMC: 10709030. DOI: 10.1016/j.bbrep.2023.101552.

Mechanistic insights into the alterations and regulation of the AKT signaling pathway in diabetic retinopathy.

Li J, Chen K, Li X, Zhang X, Zhang L, Yang Q Cell Death Discov. 2023; 9(1):418.

PMID: 37978169 PMC: 10656479. DOI: 10.1038/s41420-023-01717-2.

Increased SEMA6B expression as a potential prognostic and immune cell infiltration biomarker in thyroid cancer patients.

Lei Q, Wang Y, Li J, Wang S, Hu Y, Duan L Aging (Albany NY). 2023; 15(9):3572-3585.

PMID: 37155149 PMC: 10449300. DOI: 10.18632/aging.204691.

References

Li F, Sethi G . Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010; 1805(2):167-80. DOI: 10.1016/j.bbcan.2010.01.002. View

Galluzzi L, Larochette N, Zamzami N, Kroemer G . Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene. 2006; 25(34):4812-30. DOI: 10.1038/sj.onc.1209598. View

Del Bianco C, Aster J, Blacklow S . Mutational and energetic studies of Notch 1 transcription complexes. J Mol Biol. 2007; 376(1):131-40. PMC: 2766816. DOI: 10.1016/j.jmb.2007.11.061. View

Chen W, Bai L, Wang X, Xu S, Belinsky S, Lin Y . Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol. 2009; 77(3):416-23. PMC: 2835422. DOI: 10.1124/mol.109.061226. View

Salmena L, Carracedo A, Pandolfi P . Tenets of PTEN tumor suppression. Cell. 2008; 133(3):403-14. DOI: 10.1016/j.cell.2008.04.013. View

Kulke M, Wu B, Clark J, Enzinger P, Lynch T, Vincitore M . A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 2006; 24(3):229-34. DOI: 10.1080/07357900600633924. View

Nefedova Y, Cheng P, Alsina M, Dalton W, Gabrilovich D . Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2003; 103(9):3503-10. DOI: 10.1182/blood-2003-07-2340. View

Davies M, Koul D, Dhesi H, Berman R, McDonnell T, McConkey D . Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 1999; 59(11):2551-6. View

Wen Y, Gorsic L, Wheeler H, Ziliak D, Huang R, Dolan M . Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011; 21(8):476-88. PMC: 3134538. DOI: 10.1097/FPC.0b013e3283481967. View

10.

Hsieh J, Zhou S, Chen L, Young D, Hayward S . CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A. 1999; 96(1):23-8. PMC: 15086. DOI: 10.1073/pnas.96.1.23. View

11.

Hernandez-Aya L, Gonzalez-Angulo A . Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011; 16(4):404-14. PMC: 3228119. DOI: 10.1634/theoncologist.2010-0402. View

12.

Abedini M, Muller E, Bergeron R, Gray D, Tsang B . Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene. 2009; 29(1):11-25. DOI: 10.1038/onc.2009.300. View

13.

Chappell W, Green T, Spengeman J, McCubrey J, Akula S, Bertrand F . Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle. 2005; 4(10):1389-95. DOI: 10.4161/cc.4.10.2028. View

14.

Li Z, Oh D, Nakamura K, Thiele C . Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer. 2011; 117(23):5412-22. PMC: 3158972. DOI: 10.1002/cncr.26133. View

15.

Kao H, Ordentlich P, Tang Z, Downes M, Kintner C, Evans R . A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 1998; 12(15):2269-77. PMC: 317043. DOI: 10.1101/gad.12.15.2269. View

16.

Kunnimalaiyaan M, Chen H . Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist. 2007; 12(5):535-42. DOI: 10.1634/theoncologist.12-5-535. View

17.

Hay N . Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta. 2011; 1813(11):1965-70. PMC: 3427795. DOI: 10.1016/j.bbamcr.2011.03.013. View

18.

Sjolund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S . Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2007; 118(1):217-28. PMC: 2129233. DOI: 10.1172/JCI32086. View

19.

Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung L . Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene. 2009; 29(2):201-13. PMC: 4976641. DOI: 10.1038/onc.2009.323. View

20.

Basu B, Yap T, Molife L, de Bono J . Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol. 2012; 24(3):316-24. DOI: 10.1097/CCO.0b013e32835280c6. View